Skip to main content
OpenTrials

Clinical trial condition

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Explore clinical trials studying Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Study availability and eligibility vary by location and protocol.

601 public trials 70 recruiting studies
Refine in advanced search Browse all conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive trial results

Completed

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

NCT00375219

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myeloid Leukemia, +11 more
Locations
  • Teva Investigational Site 003 Los Angeles, California, United States
  • Teva Investigational Site 007 Jacksonville, Florida, United States
  • Teva Investigational Site 006 Atlanta, Georgia, United States
  • Teva Investigational Site 008 Beech Grove, Indiana, United States
View all 32 locations
View Trial Details
Completed

European Stop Tyrosine Kinase Inhibitor Study

NCT01596114

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myeloid Leukemia, +11 more
Locations
  • Fakultní nemocnice Brno, Czechia
  • Fakultní nemocnice Hradec Králové Hradec Králové, Czechia
  • University Hospital Olomouc Olomouc, Czechia
  • University Hospital Plzen Pilsen, Czechia
View all 50 locations
View Trial Details
Completed

Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)

NCT00412360

Conditions
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Bone Marrow Diseases, +24 more
Locations
  • University of Alabama Birmingham, Alabama, United States
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • City of Hope National Medical Center Duarte, California, United States
  • Childrens Hospital at Oakland Oakland, California, United States
View all 38 locations
View Trial Details
Completed

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

NCT03647215

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Blast Crisis, Blastic Phase Chronic Myelogenous Leukemia, +20 more
Locations
  • Limerick University Hospital Limerick, Dooradoyle, Ireland
  • University Hospital Waterford Waterford, Ireland
  • Royal Cornwall Hospital Truro, Cornwall, United Kingdom
  • Royal Devon & Exeter Hospital Exeter, Devon, United Kingdom
View all 33 locations
View Trial Details
Completed

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

NCT00171249

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Bone Marrow Diseases, +23 more
Locations
  • Dana Faber Cancer Institute Boston, Massachusetts, United States
  • New York Presbyterian Hospital New York, United States
  • Oregon Health & Sciences University Portland, Oregon, United States
  • MD Anderson Cancer Center, University of Texas Houston, Texas, United States
View Trial Details
Completed

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

NCT00171223

Conditions
Bone Marrow Diseases, Chromosome Aberrations, Chronic Disease, +20 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • H. Lee Moffet Cancer Center & Research Institute/Univ of South Florida Tampa, Florida, United States
  • Northwestern Univ meical School/Robert H. Lurie Comprehensive Cancer Center Chicago, Illinois, United States
  • Johns Hopkins Oncology Center Baltimore, Maryland, United States
View all 28 locations
View Trial Details
Completed

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.

NCT01743989

Conditions
Bone Marrow Diseases, Chronic Disease, Disease Attributes, +17 more
Locations
  • Novartis Investigative Site Linz, Upper Austria, Austria
  • Novartis Investigative Site Graz, Austria
  • Novartis Investigative Site Linz, Austria
  • Novartis Investigative Site Linz, Austria
View all 208 locations
View Trial Details

Related conditions